References
- Plosker G L, et al. Rituximab, a review of its use in non-Hodgkin's lymhoma and chronic lymphocytic leukaemia. Drugs 2003; 63: 803–843
- Huhn D, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001; 98: 1326–1331
- O'Brien S M, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 2165–2170
- Byrd J C, et al. Rituximab using thrice weekly dosing schedule in B-CLL and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001; 19: 2153–2164
- Hainsworth J D, et al. Single-agent rituximab as first-line and maintenance treatment for patients with CLL or small lymphocytic lymphoma. J Clin Oncol 2003; 21: 1746–1751
- McLaughlin P, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833
- Keating M J, et al. Emerging information on the use of rituximab in chronic lymphocytic leukemia. Semin Oncol 2002; 29(Suppl 2)70–74
- Cheson B D, et al. National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997
- Golay J, M Lazzari, V Faccinatti, et al. CD 20 levels determine the in vitro susceptibility to rituximab and complement of B cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001; 98: 3383–3389
- Jilani I, et al. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood 2003; 102: 3514–3520
- Manshouri T, Kim-anh Do, Wang X, et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 2003; 101: 2507–2513
- Gordan L N, Grow W B, Pusateri A, et al. Phase 2 trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 2005; 23: 1096–1102